The absorption of levodopa
can be reduced by 30 to 50% by ferrous sulfate
due to levodopa
chelation. Therefore all iron
compounds are expected to act similarly. Carbidopa levels are also reduced. There is some evidence that this interaction causes a decrease in symptom control
Separating the administration
of the iron
as much as possible is likely to be an effective way of managing this interaction.